The market research shows that the sales of Tocilizumab have had an increasing trend from 2016 to 2020. Since Tocilizumab was approved for the new indication sJIA in 2016, the sales increase in 2017 with 21.30% of the growth rate from 2016 to 2017. With the inclusion of Tocilizumab in China's medical insurance in 2019 and the approval of its new indications in China in 2020, the sales in 2020 increased evidently, from CNY20.07 million in 2019 to CNY41.72 million in 2020. The growth rate is about 107.89%. The CAGR of Tocilizumab was 16.25% from 2016 to 2020.
According to the market research, as the Tocilizumab market will expand from 2021 to 2025, its sales will continue to grow. The patent for the original tocilizumab injection has expired but no biosimilar drug has been approved in China. Currently, five pharmaceutical companies are carrying out relevant clinical trials. After Tocilizumab biosimilars are approved in the market, its manufacturers will gradually increase, the market will continue to grow and the price will decline. These situations will lead to an increase in Tocilizumab sales value and sales volume. In addition, Tocilizumab has been approved for 5 indications in other countries and China has approved 3 indications, so the number of approved indications in China has upside potential. It can be predicted that with the increase of indications, its sales will continue to grow with the expansion of the market in the future.
- The impact of COVID-19 on China's Tocilizumab market
- Sales value of China's Tocilizumab 2016-2020
- Competitive landscape of China's Tocilizumab market
- Prices of Tocilizumab in China
- Prices of Tocilizumab in China by regions and manufacturers
- Analysis of factors affecting the development of China's Tocilizumab market
- Prospect of China's Tocilizumab market from 2021 to 2025
1.1 Indications for Tocilizumab
1.2 Development of Tocilizumab in China
1.3 Governmental Approval of Tocilizumab in China
1.4 The Impact of COVID-19 on Tocilizumab sales in China
2 Sales of Tocilizumab in China, 2016-2020
2.1 Sales Value of Tocilizumab
2.1.1 Overall Sales Value
2.1.2 Sales Value by Regions
2.2 Sales Volume of Tocilizumab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Tocilizumab by Dosage Form in China, 2016-2020
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Tocilizumab Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Tocilizumab Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Roche Pharma (Schweiz) AG
3.2.1 Enterprise Profile
3.2.2 Sales of ACTEMRA (Roche Pharma (Schweiz) AG's Tocilizumab) in China
4 Prices of Tocilizumab for Different Manufacturers in China, 2020-2021
4.1 Roche Pharma (Schweiz) AG (ACTEMRA)
5 Prospect of Chinese Tocilizumab Market, 2021-2025
5.1 Influential Factors of Chinese Tocilizumab Market Development
5.1.1 The Impact of COVID-19 on Chinese Tocilizumab Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Tocilizumab Injection Registration in China
Chart Sales Value of Tocilizumab Injection over the World
Chart Sales Value of Tocilizumab Injection in China, 2016-2020
Chart Sales Value of Tocilizumab Injection in China by Regions, 2016-2020
Chart Sales Volume of Tocilizumab Injection in China, 2016-2020
Chart Sales Volume of Tocilizumab Injection in China by Regions, 2016-2020
Chart Market Share by Sales Value of Top Tocilizumab Manufacturers in China, 2016-2020
Chart Sales Value and Volume of ACTEMRA in China, 2016-2020
Chart Referential Prices of ACTEMRA in China by regions, 2020-2021
Chart Forecast on Sales Value of Tocilizumab in China, 2021-2025
Chart Forecast on Sales Volume of Tocilizumab in China, 2021-2025
- Roche Pharma (Schweiz) AG
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.